科研动态PubMed 摘要

帕妥珠单抗用于HER2阳性乳腺癌:随机对照试验的系统评价与荟萃分析。

PubMed 学科轮询 · 2026-11-09

完整摘要 · 中文译文

背景:HER2阳性乳腺癌是一种独特的亚型,在未接受靶向治疗的情况下与较差预后相关。帕妥珠单抗联合曲妥珠单抗的双重HER2阻断与单药方案相比显示出更好的疗效,但各项研究结果仍存在差异。本荟萃分析旨在评估以帕妥珠单抗为基础的治疗方案的整体疗效和安全性。 方法:对PubMed、Scopus、Web of Science和Cochrane Library进行了系统检索,以识别相关随机对照试验(RCT)。使用ROB-2工具评估试验质量,使用GRADE工具评估证据确定性。数据使用R软件进行合成。 结果:本研究纳入8项RCT,共8367例患者。以帕妥珠单抗为基础的治疗方案与总生存期改善相关。在局部晚期或转移性 setting 中,观察到显著获益(HR = 0.71,95% CI 0.65-0.77)。然而,在新辅助或辅助 setting 中,汇总风险比(HR = 0.81,95% CI 0.22-3.04)无统计学意义。无进展生存期(HR 0.74;95% CI 0.67-0.83)较对照组改善。在安全性方面,试验组与对照组之间任何不良事件发生率(风险比(RR)= 1.01;95% CI 0.99-1.02)或≥3级不良事件发生率(RR 0.99;95% CI 0.86-1.13)均无显著差异。 结论:以帕妥珠单抗为基础的双重HER2阻断与转移性HER2阳性乳腺癌患者总生存期和无进展生存期的显著改善相关。重要的是, 生存获益并未伴随总体不良事件或严重不良事件的显著增加,支持其在不同临床环境中具有良好的疗效-安全性特征。

完整摘要 · 英文原文

BACKGROUND: HER2-positive breast cancer is a distinct subtype associated with less favorable outcomes without targeted therapy. Dual HER2 blockade with pertuzumab and trastuzumab has shown improved efficacy compared to single-agent approaches, but results across studies remain variable. This meta-analysis aims to evaluate the overall efficacy and safety of pertuzumab-based regimens. METHODS: A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted to identify relevant RCTs. The quality of trials was assessed using the ROB-2 tool, and the certainty of the evidence was assessed using the GRADE tool. Data were synthesized using R. RESULTS: This study included 8 RCTs with 8367 patients. Pertuzumab-based regimens were associated with improved overall survival. In the locally advanced or metastatic setting, a pronounced benefit was observed (HR = 0.71, 95% CI 0.65-0.77). However, in the neoadjuvant or adjuvant setting, the pooled hazard ratio (HR = 0.81, 95% CI 0.22-3.04), which was not significant. Progression-free survival (HR 0.74; 95% CI 0.67-0.83) was improved compared with the control group. In terms of safety, there was no significant difference in the incidence of any adverse events (risk ratio (RR) = 1.01; 95% CI 0.99-1.02) or grade ≥ 3 adverse events (RR 0.99; 95% CI 0.86-1.13) between the experimental and control groups. CONCLUSION: Pertuzumab-based dual HER2 blockade is associated with significant improvements in overall survival and progression-free survival in patients with metastatic HER2-positive breast cancer. Importantly, these survival benefits are not accompanied by a significant increase in overall or severe adverse events, supporting its favorable efficacy-safety profile across clinical settings.

English
Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界